SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5187)6/22/1998 9:26:00 AM
From: Mr. Sam  Read Replies (1) | Respond to of 9719
 
I have an opportunity to buy into the upcoming IPO of GenVec. They are expected to go public this week. Are their any thoughts among the more biotech-saavy about the competitive position of their angiogenesis and anti-angiogenesis research pipeline?

Thanks for any help,
Mr. Sam



To: Rocketman who wrote (5187)6/22/1998 5:44:00 PM
From: Vector1  Read Replies (1) | Respond to of 9719
 
GENZ, got hit today on IMO unfounded rumors of impending competition for Gauchers Disease. It is a STEAL at 23 and change.

ARQL and Aurora, two of the best platform companies, have lost 70% of their market cap. WOW.

V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News